Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Vipul M. Patil has a total of 4 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Unlocking Anti-Inflammatory Potential: Virtual Discovery and ADMET Evaluation of Novel Pyrazole-Based COX-II Inhibitors

    by Vipul M. Patil, Harinath N. More

    Background Inflammation, a complex biological process mediated by arachidonic acid metabolites, plays a crucial role in various diseases like arthritis, psoriasis and neurodegenerative disorders. The Cyclooxygenase (COX) pathway, particularly COX-2, is a well-established anti-inflammatory target. Materials and Methods This study aimed to discover and evaluate novel pyrazole derivatives as potential COX-2 inhibitors via virtual screening. The 3D crystal structure of Cyclooxygenase-II (PDB: 1CX2) was prepared and optimized for in-silico investigations. Molecular docking analysis using AutoDock Vina assessed ligand-protein interactions, guided by CASTp3.0-predicted binding sites. Ligands were energy minimized and docked against the protein and drug-likeness/synthetic accessibility was predicted using SwissADME and pkCSM. Biological activity and medicinal chemistry were assessed using network diagrams, Bioavailability Radar and BOILED-Egg model for absorption and brain penetration prediction. This integrated approach facilitates the identification of potential COX-2 inhibitors with favorable pharmacokinetic profiles for further development. Results Through molecular docking, three compounds (D202, D305 and F505) exhibited the highest binding affinity for COX-2, surpassing the native ligand’s residual binding. Subsequent ADMET prediction revealed promising pharmacokinetic properties, including significant oral bioavailability scores (0.55) and synthetic feasibility scores ranging from 3.05 to 3.74. Conclusion These findings suggest the potential of these pyrazole derivatives as promising lead candidates for further development as novel anti-inflammatory agents.


  • Anti-Cancer Potential of Salaciaoblonga Wall Compounds by Targeting 5HZN and 1Q1A Receptor: A Comprehensive Molecular Docking and Simulation Approaches

    by Suraj S. Tarihalkar, Vipul Patil, Sachin Kumar Patil

    Plants produce phytochemicals with pharmacological properties that have been demonstrated in various conditions. In-silico techniques like molecular docking and virtual screening are being used to clarify the pharmacological aspects of bioactive chemicals of botanical origin. Aromatherapy has focused on plant secondary metabolites' anti-inflammatory, antioxidant, and anticancer capabilities. Essential oils contain monoterpenes and sesquiterpenes, which have several pharmacological activities. Salaciaoblongais a perennial plant with a long tradition of use in Ayurvedic medicine. It contains polyphenols, triterpenes of the friedelane and norfriedelane kinds, sesquiterpenes of the eudesmane type, and glycosides. The extract has positive pharmacological effects due to its interactions with molecular targets inside the human body. The primary goals of the current investigation were to investigate the bioactive compounds and isolates of Salaciaoblonga Wall extract with the receptors 5HZN (BRCA 3) and 1Q1A (IR). Bioactive compounds included 2,4- dimethylamphetamine, 19-hydroxyferruginol, Cyclotrisiloxane, Dulcitol, Epicatechin, Galactinol, Hexadecanoic acid, Kotalagenin-16-acetate, Kotalanol, Lambertic acid, Mangiferin, Neokotalanol, Neosalacinol, Quercetin, Raffinose, Salaciaoblonga Wall, Salasone A, Salasol B, Salasone C, Salasone D, Salasone E, Stachyose, and Trichloroacetic acid. Autodock 4.2.6 was used to dock these compounds to a chosen protein. Molecular docking data was used to identify the optimal binding conformation of inhibitors to enzymes, and protein-ligand complexation provided information on interactions. Salaciaoblonga had the best docking positions and free energy scores, but some had substandard ADME characteristics. This study paves the way for the development of novel medications against cancer-associated molecular targets.


  • Open Access

    Enlarging the NSAIDs Family: Molecular Docking of Designed Pyrazole and Oxadiazole Derivatives as Novel Anti-Inflammatory Agents

    by Vipul M. Patil, Harinath N. More

    The development of the NSAID family has represented a excitingapproach in the treatment of inflammatory disorders, such as arthritis, and for the management of acute pain, in relation to the well-known traditional Non-Steroidal Anti-Inflammatory Drugs (t-NSAIDs). Over the years, research has shown that essential mediators such as arachidonic acid metabolites are important in inflammation. The cyclooxygenase (COX) and lipoxygenase (LOX) pathways take primary roles in inflammation and are responsible for many human diseases, such as cancer, arthritis, psoriasis, and neurological disorders. Prompted by the pursuit for new cyclooxygenase-2 (COX-2) inhibitors, we have identified novel classes of pyrazole and oxadiazole derivatives as potentially powerful anti-inflammatory molecules. This virtual screening aims to predict the binding affinity of newly designed pyrazole and oxadiazole derivatives against potential molecular targets related to the inflammatory process through the molecular docking approach. Results showed very good anti-inflammatory activity against cyclooxygenase-2 (COX-2) binding protein 1CX2. Additionally, based on the molecular docking results, it was observed that two molecules have good binding affinity with a targeted protein. The issues gained with these classes of compounds represent, currently, a potent stimulus for the further enlargement of the NSAIDs family.